$5.06 Billion is the total value of Rock Springs Capital Management LP's 156 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AGL | New | AGILON HEALTH INC | $283,950,000 | – | 6,999,023 | +100.0% | 5.61% | – |
| GRPH | New | GRAPHITE BIO INC | $66,123,000 | – | 2,151,738 | +100.0% | 1.31% | – |
| VERV | New | VERVE THERAPEUTICS INC | $58,011,000 | – | 962,826 | +100.0% | 1.15% | – |
| LFST | New | LIFESTANCE HEALTH GROUP INC | $41,790,000 | – | 1,500,000 | +100.0% | 0.83% | – |
| BHG | New | BRIGHT HEALTH GROUP INC | $40,755,000 | – | 2,375,000 | +100.0% | 0.80% | – |
| BMEA | New | BIOMEA FUSION INC | $18,194,000 | – | 1,165,582 | +100.0% | 0.36% | – |
| RPHM | New | RENEO PHARMACEUTICALS INC | $10,534,000 | – | 1,129,024 | +100.0% | 0.21% | – |
| APLS | New | APELLIS PHARMACEUTICALS INCcall | $9,979,000 | – | 157,900 | +100.0% | 0.20% | – |
| FSTX | New | F-STAR THERAPEUTICS INC | $9,056,000 | – | 1,054,232 | +100.0% | 0.18% | – |
| DAWN | New | DAY ONE BIOPHARMACEUTICALS I | $8,510,000 | – | 373,739 | +100.0% | 0.17% | – |
| ATAI | New | ATAI LIFE SCIENCES NV | $5,828,000 | – | 315,028 | +100.0% | 0.12% | – |
| EDAP | New | EDAP TMS S Asponsored adr | $5,395,000 | – | 760,900 | +100.0% | 0.11% | – |
| TPST | New | TEMPEST THERAPEUTICS INC | $3,468,000 | – | 310,161 | +100.0% | 0.07% | – |
| ARPO | New | AERPIO PHARMACEUTICALS INC | $225,000 | – | 133,375 | +100.0% | 0.00% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| INTUITIVE SURGICAL INC | 40 | Q3 2023 | 3.4% |
| NEUROCRINE BIOSCIENCES INC | 39 | Q3 2023 | 4.8% |
| PACIRA PHARMACEUTICALS INC | 39 | Q3 2023 | 2.6% |
| ULTRAGENYX PHARMACEUTICAL IN | 39 | Q3 2023 | 1.9% |
| ACADIA HEALTHCARE COMPANY IN | 38 | Q3 2023 | 4.4% |
| ASCENDIS PHARMA A/S | 35 | Q3 2023 | 1.3% |
| INVITAE CORP | 35 | Q3 2023 | 1.8% |
| BIOMARIN PHARMACEUTICAL INC | 35 | Q3 2023 | 1.3% |
| MACROGENICS INC | 35 | Q3 2023 | 0.5% |
| COLLEGIUM PHARMACEUTICAL INC | 34 | Q3 2023 | 2.1% |
View Rock Springs Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 3,413,906 | 5.6% |
| Compass Therapeutics, Inc. | February 14, 2023 | 5,333,188 | 4.2% |
| Mirum Pharmaceuticals, Inc. | February 14, 2023 | 1,795,733 | 4.9% |
| PhaseBio Pharmaceuticals IncSold out | February 14, 2023 | 0 | 0.0% |
| Sierra Oncology, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ARDELYX, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| CHIASMA, INCSold out | February 15, 2022 | 0 | 0.0% |
| FIVE PRIME THERAPEUTICS, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| F-star Therapeutics, Inc. | February 15, 2022 | 751,889 | 3.6% |
| Protara Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
View Rock Springs Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-05-01 |
| SC 13G/A | 2024-04-05 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Rock Springs Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.